Skip to main content

Research Repository

Advanced Search

All Outputs (46)

Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 (2022)
Journal Article
Liu, H., Stiller, C. A., Crooks, C. J., Rous, B., Bythell, M., Broggio, J., …West, J. (2022). Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019. British Journal of Haematology, 199(5), 728-738. https://doi.org/10.1111/bjh.18459

This analysis is the largest population-based study to date to provide contemporary and comprehensive epidemiological estimates of all third edition of the International Classification of Diseases for Oncology (ICD-O-3) coded Langerhans cell histiocy... Read More about Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019.

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (2022)
Journal Article
Nastoupil, L., Morschhauser, F., Scholz, C. W., Bishton, M., Yoon, S.-S., Giri, P., …Bartlett, N. L. (2022). P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere, 6(S3), 1015-1016. https://doi.org/10.1097/01.HS9.0000847368.92731.fb

Temporal trends in the incidence of haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003-2018 (2022)
Preprint / Working Paper
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T. R., …Crooks, C. J. Temporal trends in the incidence of haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003-2018

Background Haemophagocytic lymphohistiocytosis (HLH) is rare, results in high mortality and is increasingly being diagnosed. Little is known about what is driving the apparent rise in the incidence of this disease.

Methods Using national linked el... Read More about Temporal trends in the incidence of haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003-2018.

The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe (2022)
Journal Article
Bishton, M., Marshall, S., Harchowal, J., Salles, G., Golfier, C., Tucci, A., …Zinzani, P. L. (2022). The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe. Hematological Oncology, 40(3), 370-380. https://doi.org/10.1002/hon.2978

Rapid infusion (RI) of the rituximab biosimilar CT-P10 is currently only an approved treatment regimen for the treatment of rheumatoid arthritis. Although both CT-P10 and reference rituximab are known to be frequently administered using a RI regimen... Read More about The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe.

Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England (2021)
Journal Article
West, J., Card, T. R., Bishton, M. J., Lanyon, P., Ban, L., Bythell, M., …Crooks, C. J. (2022). Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England. Journal of Internal Medicine, 291(4), 493-504. https://doi.org/10.1111/joim.13432

Background: Haemophagocytic lymphohistiocytosis (HLH) is a rare hyper-inflammatory condition with poor outcomes. Objectives: Few population-based estimates of the incidence and survival in adults exist. We aimed to provide these data for England. Met... Read More about Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England.

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study (2021)
Journal Article
Wang, M., Ramchandren, R., Chen, R., Karlin, L., Chong, G., Jurczak, W., …Tam, C. S. (2021). Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. Journal of Hematology and Oncology, 14, Article 179. https://doi.org/10.1186/s13045-021-01188-x

Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administer... Read More about Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.

Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data (2021)
Journal Article
Halligan, S. J., Grainge, M. J., Martinez-Calle, N., Fox, C. P., & Bishton, M. J. (2022). Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data. British Journal of Haematology, 196(4), 932-938. https://doi.org/10.1111/bjh.17896

Systemic anaplastic large cell lymphoma (sALCL) is a rare T-cell lymphoma associated with poor prognosis after relapse. The immuno-conjugate Brentuximab Vedotin (BV) first became available for relapsed sALCL in England in 2013, following the results... Read More about Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data.

A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data (2021)
Journal Article
Bishton, M. J., Stilwell, P., Card, T. R., Lanyon, P., Ban, L., Elliss-Brookes, L., …Bythell, M. (2021). A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data. British Journal of Haematology, 194(6), 1039-1044. https://doi.org/10.1111/bjh.17768

We assessed the validity of coded healthcare data to identify cases of haemophagocytic lymphohistiocytosis (HLH). Hospital Episode Statistics (HES) identified 127 cases within five hospital Trusts 2013–2018 using ICD-10 codes D76.1, D76.2 and D76.3.... Read More about A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data.

Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom (2021)
Journal Article
Kaji, F. A., Martinez‐Calle, N., Bishton, M. J., Figueroa, R., Adlington, J., O’Donoghue, M., …Fox, C. P. (2021). Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. British Journal of Haematology, 195(4), 561-570. https://doi.org/10.1111/bjh.17747

Observational studies with long-term follow-up of patients with primary central nervous system lymphoma (PCNSL) are scarce. Patient data over a period of four decades were retrospectively analysed from databases at Not-tingham University Hospitals Tr... Read More about Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.

Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort (2021)
Journal Article
Martinez-Calle, N., Kirkwood, A. A., Lamb, M., Smith, A., Khwaja, J., Manos, K., …Fox, C. P. (2021). Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy, 38(7), 3789-3802. https://doi.org/10.1007/s12325-021-01764-0

Introduction: Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine... Read More about Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.

A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data (2021)
Preprint / Working Paper
Bishton, M., Stilwell, P., Card, T. R., Lanyon, P., Ban, L., Elliss-Brookes, L., …Bythell, M. A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data

We assessed the validity of coded health care data to identify cases of haemophagocytic lymphohistiocytosis (HLH). Hospital Episode Statistics (HES) identified 127 cases within five hospital Trusts 2013-2018 using ICD-10 codes D76.1, D76.2 and D76.3.... Read More about A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data.

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis (2021)
Journal Article
Rampotas, A., Wilson, M. R., Lomas, O., Denny, N., Leary, H., Ferguson, G., …Eyre, T. A. (2021). Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. British Journal of Haematology, 194(2), 365-377. https://doi.org/10.1111/bjh.17513

Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line ‘attenuated’ or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenu... Read More about Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP (2021)
Journal Article
Eyre, T. A., Wilson, W., Kirkwood, A. A., Wolf, J., Hildyard, C., Plaschkes, H., …Hatton, C. S. R. (2021). Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. Blood Advances, 5(8), 2229-2236. https://doi.org/10.1182/bloodadvances.2021004286

Infection-related morbidity and mortality are increased in older patients with diffuse large B-cell lymphoma (DLBCL) compared with population-matched controls. Key predictive factors for infection-related hospitalization during treatment with rituxim... Read More about Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.

The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma (2021)
Journal Article
Barraclough, A., Bishton, M., Cheah, C. Y., Villa, D., & Hawkes, E. A. (2021). The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. British Journal of Haematology, 195(1), 15-24. https://doi.org/10.1111/bjh.17404

Grade 3B follicular lymphoma (G3B FL) is rare, accounting for only 5–10% of FLs. Not only has it been routinely excluded from clinical trials, but data published on diagnosis, outcomes, choice of therapies and role of imaging are conflicting. With th... Read More about The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma.

Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax (2020)
Journal Article
Figueroa, R., Martinez‐Calle, N., Prescott, K., & Bishton, M. (2020). Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax. eJHaem, 1(2), 418-419. https://doi.org/10.1002/jha2.121

An 80-year-old male, with relapsed mantle cell lymphoma was treated on a trial with the combination of the bruton tyrosine kinase (BTK) inhibitor, ibrutinib, and BH3-mimetic, venetoclax, and achieved complete remission by both Computerized Tomography... Read More about Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax.

Extended follow‐up of CD4 + T cell recovery kinetics in a large cohort of patients with B‐cell lymphoproliferative disease treated with rituximab‐bendamustine (2020)
Journal Article
Gaiolla, R., Hartley, S., Beech, A., Knight, H., Smith, D., Bishton, M., …Martinez-Calle, N. (2021). Extended follow‐up of CD4 + T cell recovery kinetics in a large cohort of patients with B‐cell lymphoproliferative disease treated with rituximab‐bendamustine. Hematological Oncology, 39(1), 137-140. https://doi.org/10.1002/hon.2797

The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival (2020)
Journal Article
Bishton, M. J., Rule, S., Wilson, W., Turner, D., Patmore, R., Clifton‐Hadley, L., …Haynes, A. (2020). The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival. British Journal of Haematology, 190(4), 545-554. https://doi.org/10.1111/bjh.16555

We present a long-term follow-up of the UK chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced, symptomatic follicular lymphoma (FL). This trial was the first to prospecti... Read More about The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2019)
Journal Article
E, G.-B., A, B., D, B., M, T., T, M., H, F., …A, S. (2020). Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 55(2), 393-399. https://doi.org/10.1038/s41409-019-0650-x

Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line chemoimmunotherapy. Long-term outcome of those who relapse after tran... Read More about Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity (2019)
Journal Article
Eyre, T. A., Kirkwood, A. A., Wolf, J., Hildyard, C., Mercer, C., Plaschkes, H., …Hatton, C. S. R. (2019). Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. British Journal of Haematology, 187(2), 185-194. https://doi.org/10.1111/bjh.16070

Central nervous system (CNS) relapse following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) occurs in 2–5% of patents with diffuse large B-cell lymphoma (DLBCL). Many patients aged ≥70 years are unsuitable for high-dos... Read More about Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.